FDA has heeded the advice of stakeholders and eliminated its recommendation that manufacturers of generic abuse-deterrent opioids compare the brand to a control product for certain studies.
The agency's draft guidance to assist industry in developing generic versions of approved abuse-deterrent formulations (ADFs) advised that for certain comparative studies, such as extractability studies, discriminatory conditions should be identified by including a control product and comparing it to the
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?